Prostate Cancer After a Radical TreatmentBiochemical Recurrence of Malignant Neoplasm of ProstateBiochemical Persistence of Prostate Cancer
Study summary
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Informed Consent
* Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care
Exclusion Criteria:
* Technical Flaws in the acquisition protocol
Primary outcome measure(s)
PSA-Stratified Detection rate of [18F]PSMA-1007 in BCR — From the timepoint of recruitment on for a time frame of 6 months for each individual Assessment of detection rate of molecular imaging in accordance with composite reference method or histopathological validation, if available
Clinical Impact — From the timepoint of recruitment on for a time frame of 6 months for each individual The assesment of the anticipated rate of therapy change based on the PSMA-PET imaging for the patients with BCR
Trial sites (1)
Facility
City
Region
Status
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Düsseldorf
North Rhine-Westphalia
Recruiting
More Heinrich-Heine University, Duesseldorf trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.